Browse studies

Find your next paid study

700 recruiting studies matching your filters

Phase I Study of Gilteritinib for ALK Positive Non-Small Cell Lung Cancer

This phase I trial is studying the safety, side effects, and best dose of gilteritinib in treating patients with stage IV ALK positive non-small cell lung canc…

Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8

Estimated

~$10 – $6,250

University of Michigan Rogel Cancer CenterNCT06225427

Phase 1

A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of Subcutaneous Tarlatamab in Subjects With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)

The primary objective of this study is to evaluate the safety and tolerability of subcutaneous (SC) tarlatamab.

Extensive Stage Small Cell Lung Cancer

Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer

This is a phase II trial of adjuvant chemotherapy and immunotherapy for completely resected small cell lung cancer (SCLC).

Small Cell Lung Cancer (SCLC)

Estimated

~$10 – $6,250

Alliance Foundation Trials, LLC.NCT07149363

Observational

Prediction Augmented Screening Initiative

Lung cancer is responsible for more deaths in the United States than breast, prostate and colon cancer combined and is the number one cancer killer of Veterans…

Lung CancerLung Cancer Screening

Estimated

~$10 – $5,625

VA Office of Research and DevelopmentNCT06538636

Phase 3

LUNAR-2: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab and Platinum-based Chemotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer

This study, known as LUNAR-2, aims to investigate the effectiveness and safety of using TTFields, delivered by the NovoTTF-200T device, concomitantly administe…

Metastatic Non-small Cell Lung Cancer

Estimated

~$10 – $8,750

NovoCure GmbHNCT06216301

EGFR Pathway Mutations in Lung Cancer Patient Tumors and Blood

RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA a…

Lung Cancer

Estimated

~$10 – $750

University of California, DavisNCT00899405

Phase 1

A Global First-in-Human Study in NSCLC, HNSCC, and Solid Tumors With Azirkitug as a Single Agent and in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease …

Non-Small Cell Lung CancerHead and Neck Squamous Cell CarcinomaMicro Satellite Stable Colorectal Cancer+4 more

A Phase Ia/Ib, Open Label, Multi-center, Non-randomized Dose Escalation and Dose Expansion Study of RSC-1255 Alone or in Combination With Hydroxychloroquine in Patients With Advanced Solid Tumor Malignancies

RSC-101 is a Phase 1a/1b clinical trial of RSC-1255 in adult study participants with advanced solid tumor malignancies who are intolerant of existing therapies…

Advanced Malignant Solid NeoplasmRAS MutationLung Cancer+3 more

Estimated

~$10 – $8,750

RasCal Therapeutics, Inc.NCT04678648

Phase 3

A Phase 3, Multicenter, Randomized, Controlled, Open-Label Clinical Trial of Aglatimagene Besadenovec (CAN-2409) Plus Prodrug and Pembrolizumab Versus Docetaxel for Stage IV Non-Squamous Non-Small Cell Lung Cancer Progressing on Pembrolizumab-based Treatment

This phase III trial compares the effect of the combination of aglatimagene besadenovec and pembrolizumab versus standard of care docetaxel chemotherapy for th…

Non-squamous, Non-Small Cell Lung Cancer

Estimated

~$10 – $8,750

Candel Therapeutics, Inc.NCT07660094

Phase 1

A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors

This is a FIH study is to evaluate the safety, tolerability, PK, immunogenicity, and preliminary antitumor activity of XB010 as a single agent and in combinati…

Locally Advanced or Metastatic Solid TumorsEsophageal Squamous Cell CancerHead and Neck Squamous Cell Cancer+3 more

Phase II Trial: Photoimmunotherapy and Anti-PD1 in Patients With Refractory Inoperable and Metastatic Non-Small Cell Lung Cancer

This phase II trial tests how well photoimmunotherapy (PIT) with ASP-1929 in combination with cemiplimab works in treating patients with stage IIIB-IV non-smal…

Lung Non-Small Cell CarcinomaMetastatic Lung Non-Small Cell CarcinomaRefractory Lung Non-Small Cell Carcinoma+3 more

Estimated

~$10 – $7,500

Roswell Park Cancer InstituteNCT06943664

Maximizing Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types

This study explores the role of T cells in monitoring disease status and response during anti-PD-1/PD-L1 treatment in patients with melanoma, lung and other ca…

Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Locally Advanced Lung Carcinoma+7 more

Estimated

~$10 – $750

Mayo ClinicNCT06075524